cas 91007-16-8|| where to buy ethyl 4-ethyl-3-oxohexanoate

Produktname:ethyl 4-ethyl-3-oxohexanoate

IUPAC Name:ethyl 4-ethyl-3-oxohexanoate

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM397500-1000g	3-4 Weeks	ŵȡũƥ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 91007-16-8 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:91007-16-8; Molekulare Formel:C10H18O3; Schmelzpunkt:-; SMILES-Code:CCOC(=O)CC(=O)C(CC)CC; Dichte:

: Katalognummer:CM397500; Molekulargewicht:186.25; Siedepunkt:; Mdl-Nr.:; Lagerung:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: KB-0742; Kronos Bio announces the first patient dosed in an expansion cohort with KB-0742 at a dose of 80mg given on a four-days-on, three-days-off schedule. This expansion cohort is enrolling platinum-resistant patients with high-grade serous ovarian cancer (HGSOC). Many cancers exhibit transcriptional deregulation, often characterized by gene amplifications of MYC family oncogene. Targeting the transcription elongation cofactor, cyclin-dependent kinase 9 (CDK9) has emerged as a therapeutic strategy to disrupt MYC oncogenic activity.
KB-0742 is an oral highly selective CDK9 inhibitor designed for the treatment of patients with MYC-amplified and other transcriptionally addicted relapsed or refractory solid tumors, including ovarian, lung, and triple-negative breast cancers.